Method for preparing amorphous tildipirosin
The present invention relates to a method for preparing amorphous tildipirosin. The amorphous tildipirosin has an endothermic peak at 135-171 DEG C and has an exothermic peak at 186-210 DEG C in a TG-DSC spectrum and has no recognizable diffraction peak in an XPRD spectrum. The preparation method co...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | HOU BAOHONG GONG DUNBEI CHEN XIAOLIN WU SONGGU CAO JIANDONG HE LINHUA XIANG YI |
| description | The present invention relates to a method for preparing amorphous tildipirosin. The amorphous tildipirosin has an endothermic peak at 135-171 DEG C and has an exothermic peak at 186-210 DEG C in a TG-DSC spectrum and has no recognizable diffraction peak in an XPRD spectrum. The preparation method comprises steps as follows: selecting isopropyl ether as a solvent for dissolution, then adding water to precipitate solids, and drying a wet sample thoroughly after filtration to obtaining an amorphous product. The amorphous product has good stability and can be preserved for a long period without degradation. The amorphous tildipirosin is used for preparing a pharmaceutical preparation, and the dosage form of the pharmaceutical preparation can be premix, tablets, pills, powder, granules, capsules or injections. Compared with other crystal forms of tildipirosin, the amorphous tildipirosin has better solubility and higher bioavailability.
本发明涉及种泰地罗新无定型制备方法。该泰地罗新无定型在TG-DSC图谱中在135℃～171℃之间有吸热峰在186℃～210℃之间有放热峰；其XPRD图谱没有可 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN106046086A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN106046086A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN106046086A3</originalsourceid><addsrcrecordid>eNrjZND2TS3JyE9RSMsvUigoSi1ILMrMS1dIzM0vKsjILy1WKMnMScksyCzKL87M42FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hgZmBiZmBhZmjsbEqAEAmJwp-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Method for preparing amorphous tildipirosin</title><source>esp@cenet</source><creator>HOU BAOHONG ; GONG DUNBEI ; CHEN XIAOLIN ; WU SONGGU ; CAO JIANDONG ; HE LINHUA ; XIANG YI</creator><creatorcontrib>HOU BAOHONG ; GONG DUNBEI ; CHEN XIAOLIN ; WU SONGGU ; CAO JIANDONG ; HE LINHUA ; XIANG YI</creatorcontrib><description>The present invention relates to a method for preparing amorphous tildipirosin. The amorphous tildipirosin has an endothermic peak at 135-171 DEG C and has an exothermic peak at 186-210 DEG C in a TG-DSC spectrum and has no recognizable diffraction peak in an XPRD spectrum. The preparation method comprises steps as follows: selecting isopropyl ether as a solvent for dissolution, then adding water to precipitate solids, and drying a wet sample thoroughly after filtration to obtaining an amorphous product. The amorphous product has good stability and can be preserved for a long period without degradation. The amorphous tildipirosin is used for preparing a pharmaceutical preparation, and the dosage form of the pharmaceutical preparation can be premix, tablets, pills, powder, granules, capsules or injections. Compared with other crystal forms of tildipirosin, the amorphous tildipirosin has better solubility and higher bioavailability.
本发明涉及种泰地罗新无定型制备方法。该泰地罗新无定型在TG-DSC图谱中在135℃～171℃之间有吸热峰在186℃～210℃之间有放热峰；其XPRD图谱没有可</description><language>chi ; eng</language><subject>CHEMISTRY ; DERIVATIVES THEREOF ; METALLURGY ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; SUGARS</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161026&DB=EPODOC&CC=CN&NR=106046086A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20161026&DB=EPODOC&CC=CN&NR=106046086A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HOU BAOHONG</creatorcontrib><creatorcontrib>GONG DUNBEI</creatorcontrib><creatorcontrib>CHEN XIAOLIN</creatorcontrib><creatorcontrib>WU SONGGU</creatorcontrib><creatorcontrib>CAO JIANDONG</creatorcontrib><creatorcontrib>HE LINHUA</creatorcontrib><creatorcontrib>XIANG YI</creatorcontrib><title>Method for preparing amorphous tildipirosin</title><description>The present invention relates to a method for preparing amorphous tildipirosin. The amorphous tildipirosin has an endothermic peak at 135-171 DEG C and has an exothermic peak at 186-210 DEG C in a TG-DSC spectrum and has no recognizable diffraction peak in an XPRD spectrum. The preparation method comprises steps as follows: selecting isopropyl ether as a solvent for dissolution, then adding water to precipitate solids, and drying a wet sample thoroughly after filtration to obtaining an amorphous product. The amorphous product has good stability and can be preserved for a long period without degradation. The amorphous tildipirosin is used for preparing a pharmaceutical preparation, and the dosage form of the pharmaceutical preparation can be premix, tablets, pills, powder, granules, capsules or injections. Compared with other crystal forms of tildipirosin, the amorphous tildipirosin has better solubility and higher bioavailability.
本发明涉及种泰地罗新无定型制备方法。该泰地罗新无定型在TG-DSC图谱中在135℃～171℃之间有吸热峰在186℃～210℃之间有放热峰；其XPRD图谱没有可</description><subject>CHEMISTRY</subject><subject>DERIVATIVES THEREOF</subject><subject>METALLURGY</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>SUGARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZND2TS3JyE9RSMsvUigoSi1ILMrMS1dIzM0vKsjILy1WKMnMScksyCzKL87M42FgTUvMKU7lhdLcDIpuriHOHrqpBfnxqcUFicmpeakl8c5-hgZmBiZmBhZmjsbEqAEAmJwp-A</recordid><startdate>20161026</startdate><enddate>20161026</enddate><creator>HOU BAOHONG</creator><creator>GONG DUNBEI</creator><creator>CHEN XIAOLIN</creator><creator>WU SONGGU</creator><creator>CAO JIANDONG</creator><creator>HE LINHUA</creator><creator>XIANG YI</creator><scope>EVB</scope></search><sort><creationdate>20161026</creationdate><title>Method for preparing amorphous tildipirosin</title><author>HOU BAOHONG ; GONG DUNBEI ; CHEN XIAOLIN ; WU SONGGU ; CAO JIANDONG ; HE LINHUA ; XIANG YI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN106046086A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>DERIVATIVES THEREOF</topic><topic>METALLURGY</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>SUGARS</topic><toplevel>online_resources</toplevel><creatorcontrib>HOU BAOHONG</creatorcontrib><creatorcontrib>GONG DUNBEI</creatorcontrib><creatorcontrib>CHEN XIAOLIN</creatorcontrib><creatorcontrib>WU SONGGU</creatorcontrib><creatorcontrib>CAO JIANDONG</creatorcontrib><creatorcontrib>HE LINHUA</creatorcontrib><creatorcontrib>XIANG YI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HOU BAOHONG</au><au>GONG DUNBEI</au><au>CHEN XIAOLIN</au><au>WU SONGGU</au><au>CAO JIANDONG</au><au>HE LINHUA</au><au>XIANG YI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Method for preparing amorphous tildipirosin</title><date>2016-10-26</date><risdate>2016</risdate><abstract>The present invention relates to a method for preparing amorphous tildipirosin. The amorphous tildipirosin has an endothermic peak at 135-171 DEG C and has an exothermic peak at 186-210 DEG C in a TG-DSC spectrum and has no recognizable diffraction peak in an XPRD spectrum. The preparation method comprises steps as follows: selecting isopropyl ether as a solvent for dissolution, then adding water to precipitate solids, and drying a wet sample thoroughly after filtration to obtaining an amorphous product. The amorphous product has good stability and can be preserved for a long period without degradation. The amorphous tildipirosin is used for preparing a pharmaceutical preparation, and the dosage form of the pharmaceutical preparation can be premix, tablets, pills, powder, granules, capsules or injections. Compared with other crystal forms of tildipirosin, the amorphous tildipirosin has better solubility and higher bioavailability.
本发明涉及种泰地罗新无定型制备方法。该泰地罗新无定型在TG-DSC图谱中在135℃～171℃之间有吸热峰在186℃～210℃之间有放热峰；其XPRD图谱没有可</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN106046086A |
| source | esp@cenet |
| subjects | CHEMISTRY DERIVATIVES THEREOF METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY SUGARS |
| title | Method for preparing amorphous tildipirosin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T23%3A34%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HOU%20BAOHONG&rft.date=2016-10-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN106046086A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |